S. J. Forman

Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting

This study develops TAG72-CAR T cells with antigen-dependent IL-12 signaling to enhance anti-tumor activity and systemic disease targeting in ovarian cancer.

Selective IL13Rα2-Targeted Functionality of IL13-Ligand CARs is Enhanced by Inclusion of 4-1BB Co-Stimulation

This study compares IL13-ligand CAR designs to determine how co-stimulation domains affect tumor selectivity and anti-tumor activity against glioblastoma.

PD-L1 blockade restores CAR T cell activity through IFNγ-regulation of CD163+ macrophages

This study shows that PD-L1 blockade enhances CAR T cell activity by altering macrophage phenotypes through IFNγ signaling in the tumor microenvironment.

Pre-conditioning Modifies the Tumor Microenvironment to Enhance Solid Tumor CAR T Cell Efficacy and Endogenous Immunity

This study shows that cyclophosphamide pre-conditioning improves CAR T cell efficacy against solid tumors by modifying the immunosuppressive tumor microenvironment without harming normal tissues.

Chlorotoxin Redirects Chimeric Antigen Receptor T Cells for Specific and Effective Targeting of Glioblastoma

This study develops a CAR T cell therapy using chlorotoxin to target glioblastoma with high specificity and potency, overcoming tumor heterogeneity challenges.

Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting

This study shows that daratumumab targets CD38+ NK cells to induce immune activation and anti-myeloma activity despite reducing total NK cell frequency.

Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors

This study combines oncolytic viruses with CAR T cells to deliver CD19 antigen to solid tumors, enhancing CAR T cell anti-tumor responses.